ZINC FINGER NUCLEASES (ZFN) CLINICAL TRIALS

All | CRISPR-Cas | TALENS

Antibacterial

Blood

Transfusion Dependent Beta-Thalassemia, TDT, (NCT03432364)
Sponsors:

Sangamo Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, (NCT03653247)
Sponsors:

Bioverativ, a Sanofi company

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT03666871)
Sponsors:

Case Western Reserve University

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT03617198)
Sponsors:

University of Pennsylvania

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT02500849)
Sponsors:

City of Hope Medical Center

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT02225665)
Sponsors:

Sangamo BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT01252641)
Sponsors:

Sangamo Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT01044654)
Sponsors:

Sangamo Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT00842634)
Sponsors:

University of Pennsylvania

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV (NCT02388594)
Sponsors:

University of Pennsylvania

IND Enabling

Phase I

Phase II

Phase III

Hemophilia B, (NCT02695160)
Sponsors:

Sangamo Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Hemophilia B Factor IX, (2017-004805-42)
Sponsors:

Sangamo Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Cancer

Human papillomavirus (HPV) related cervical cancer, (NCT02800369)
Sponsors:

Huazhong University of Science and Technology

IND Enabling

Phase I

Phase II

Phase III

Eye

Metabolic disorder

Mucopolysaccharidosis type I, MPS I, (NCT02702115)
Sponsors:

Sangamo Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Mucopolysaccharidosis II, MPS II, (NCT03041324)
Sponsors:

Sangamo Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Mucopolysaccharidosis I, MPS I, (2018-000206-28)
Sponsors:

Sangamo Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Mucopolysaccharidosis type II, MPS II, (2018-000192-33)
Sponsors:

Sangamo Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III